Abstract
COVID-19 is caused by coronavirus (SARS-CoV-2) is a worldwide health crisis. This severe
acute respiratory syndrome was declared an outbreak after the first case was reported in
Wuhan, the capital city of Hubei Province in China. On March 11th, 2020, the World Health
Organization (WHO) declared it as a pandemic. The pharmaceutical treatment of COVID-19 has
garnered significant critical attention due to the unavailability of medications to treat
COVID-19. Recently, researchers have shown an increased interest in the monoclonal
antibody drugs to treat COVID-19 especially REGEN-COV (casirivimab and imde-vimab). This
review aims to highlight the relation between the drug and COVID-19 and the recently
updated information on the monoclonal antibody REGEN-COV from the U.S. Food and Drug
Administration and other authorities. It is also designed to focus on the bibliometric
data of REGEN-COV for the last three years (2020, 2021, and 2021) in PubMed and Google
Scholar.